Selective inhibition of neurogenic, but not agonist-induced contractions by phospholipase A
benign prostatic hyperplasia (BPH)
lower urinary tract symptoms (LUTS)
phospholipase
prostate smooth muscle contraction
voiding symptoms
α1-adrenoceptor
α1-blocker
Journal
Neurourology and urodynamics
ISSN: 1520-6777
Titre abrégé: Neurourol Urodyn
Pays: United States
ID NLM: 8303326
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
28
06
2023
received:
04
05
2023
accepted:
29
06
2023
medline:
17
8
2023
pubmed:
16
8
2023
entrez:
16
8
2023
Statut:
ppublish
Résumé
Phospholipases A Prostate tissues were obtained from radical prostatectomy. Contractions were induced by electric field stimulation (EFS) and by α Frequency-dependent contractions of human prostate tissues induced by EFS were inhibited by 25% at 8 Hz, 38% at 16 Hz and 37% at 32 Hz by ASB14780 (1 µM), and by 32% at 16 Hz and 22% at 32 Hz by AACOCF3 (10 µM). None of both inhibitors affected contractions induced by noradrenaline, phenylephrine or methoxamine. YM26734 (3 µM) and montelukast (0.3 and 1 µM) neither affected EFS-induced contractions, nor contractions by α Our findings suggest presynaptic PLA
Sections du résumé
BACKGROUND
Phospholipases A
METHODS
Prostate tissues were obtained from radical prostatectomy. Contractions were induced by electric field stimulation (EFS) and by α
RESULTS
Frequency-dependent contractions of human prostate tissues induced by EFS were inhibited by 25% at 8 Hz, 38% at 16 Hz and 37% at 32 Hz by ASB14780 (1 µM), and by 32% at 16 Hz and 22% at 32 Hz by AACOCF3 (10 µM). None of both inhibitors affected contractions induced by noradrenaline, phenylephrine or methoxamine. YM26734 (3 µM) and montelukast (0.3 and 1 µM) neither affected EFS-induced contractions, nor contractions by α
CONCLUSIONS
Our findings suggest presynaptic PLA
Substances chimiques
montelukast
MHM278SD3E
3-(1-(4-phenoxyphenyl)-3-(2-phenylethyl)-1H-indol-5-yl)propanoic acid
0
Thromboxanes
0
Adrenergic Agonists
0
Adrenergic Agents
0
Phospholipases
EC 3.1.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1522-1531Informations de copyright
© 2023 The Authors. Neurourology and Urodynamics published by Wiley Periodicals LLC.
Références
Hennenberg M, Stief CG, Gratzke C. Prostatic α1-adrenoceptors: new concepts of function, regulation, and intracellular signaling: new concepts of prostatic α1-adrenoceptors. Neurourol Urodyn. 2014;33(7):1074-1085.
Oelke M, Bachmann A, Descazeaud A, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64(1):118-140.
Cindolo L, Pirozzi L, Sountoulides P, et al. Patient's adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy? BMC Urol. 2015;15:96.
Hennenberg M, Acevedo A, Wiemer N, et al. Non-adrenergic, tamsulosin-insensitive smooth muscle contraction is sufficient to replace α1-adrenergic tension in the human prostate. Prostate. 2017;77(7):697-707.
Hennenberg M, Miljak M, Herrmann D, et al. The receptor antagonist picotamide inhibits adrenergic and thromboxane-induced contraction of hyperplastic human prostate smooth muscle. Am J Physiol-Ren Physiol. 2013;305(10):F1383-F1390.
Hennenberg M, Tamalunas A, Wang Y, et al. Inhibition of agonist-induced smooth muscle contraction by picotamide in the male human lower urinary tract outflow region. Eur J Pharmacol. 2017;803:39-47.
Alexander SP, Fabbro D, Kelly E, et al. The concise guide to pharmacology 2021/22: enzymes. Br J Pharmacol. 2021;178(suppl 1):S313-S411.
Nakahata N. Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther. 2008;118(1):18-35.
Li B, Huang R, Wang R, Liu Y, Stief CG, Hennenberg M. Picotamide inhibits a wide spectrum of agonist-induced smooth muscle contractions in porcine renal interlobar and coronary arteries. Pharmacol Res Perspect. 2021;9(3):e00771.
Huang R, Liu Y, Hu S, et al. Inhibition of α1-adrenergic, non-adrenergic and neurogenic human prostate smooth muscle contraction and of stromal cell growth by the isoflavones genistein and daidzein. Nutrients. 2022;14(23):4943.
Tomoo T, Nakatsuka T, Katayama T, et al. Design, synthesis, and biological evaluation of 3-(1-Aryl-1H-indol-5-yl)propanoic acids as new indole-based cytosolic phospholipase A2α inhibitors. J Med Chem. 2014;57(17):7244-7262.
Riendeau D, Guay J, Weech PK, et al. Arachidonyl trifluoromethyl ketone, a potent inhibitor of 85-kDa phospholipase A2, blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. J Biol Chem. 1994;269(22):15619-15624.
Koutek B, Prestwich GD, Howlett AC, et al. Inhibitors of arachidonoyl ethanolamide hydrolysis. J Biol Chem. 1994;269(37):22937-22940.
Hamaguchi K, Kuwata H, Yoshihara K, et al. Induction of distinct sets of secretory phospholipase A(2) in rodents during inflammation. Biochim Biophys Acta-Mol Cell Biol Lipids. 2003;1635(1):37-47.
Miyake A, Yamamoto H, Kubota E, et al. Suppression of inflammatory responses to 12-O-tetradecanoyl-phorbol-13-acetate and carrageenin by YM-26734, a selective inhibitor of extracellular group II phospholipase A2. Br J Pharmacol. 1993;110(1):447-453.
Alexander SP, Christopoulos AC, Davenport AP, et al. The concise guide to pharmacology 2021/22: G protein-coupled receptors. Br J Pharmacol. 2021;178(suppl 1):S27-S156.
Murata S, Taniguchi T, Muramatsu I. Pharmacological analysis of the novel, selectiveα1-adrenoceptor antagonist, KMD-3213, and its suitability as a tritiated radioligand: KMD-3213 andα1-adrenoceptor subtypes. Br J Pharmacol. 1999;127(1):19-26.
Shibata K, Foglar R, Horie K, et al. KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. Mol Pharmacol. 1995;48(2):250-258.
Moriyama N, Akiyama K, Murata S, et al. KMD-3213, a novel α1A-adrenoceptor antagonist, potently inhibits the functional α1-adrenoceptor in human prostate. Eur J Pharmacol. 1997;331(1):39-42.
Michel MC, Murphy TJ, Motulsky HJ. New author guidelines for displaying data and reporting data analysis and statistical methods in experimental biology. Mol Pharmacol. 2020;97(1):49-60.
Steib CJ, Bilzer M, op den Winkel M, et al. Treatment with the leukotriene inhibitor montelukast for 10 days attenuates portal hypertension in rat liver cirrhosis. Hepatology. 2010;51(6):2086-2096.
Clarke DL, Dakshinamurti S, Larsson AK, Ward JE, Yamasaki A. Lipid metabolites as regulators of airway smooth muscle function. Pulm Pharmacol Ther. 2009;22(5):426-435.
Sohn UD, Hong YW, Choi HC, et al. Increase of [Ca(2+)]i and release of arachidonic acid via activation of M2 receptor coupled to Gi and rho proteins in oesophageal muscle. Cell Signal. 2000;12(4):215-222.
Araki S, Ito M, Kureishi Y, et al. Arachidonic acid-induced Ca2+ sensitization of smooth muscle contraction through activation of Rho-kinase. Pflügers Archiv. 2001;441(5):596-603.
Somlyo AP, Somlyo AV. Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol. 2000;522(Pt 2):177-185.
Gailly P, Gong MC, Somlyo AV, Somlyo AP. Possible role of atypical protein kinase C activated by arachidonic acid in Ca2+ sensitization of rabbit smooth muscle. J Physiol. 1997;500(Pt 1):95-109.
Lawandy I, Liu Y, Shi G, et al. Increased coronary arteriolar contraction to serotonin in juvenile pigs with metabolic syndrome. Mol Cell Biochem. 2019;461(1-2):57-64.
Muthalif MM, Benter IF, Uddin MR, Malik KU. Calcium/calmodulin-dependent protein kinase IIα mediates activation of mitogen-activated protein kinase and cytosolic phospholipase A2 in norepinephrine-induced arachidonic acid release in rabbit aortic smooth muscle cells. J Biol Chem. 1996;271(47):30149-30157.
Muthalif MM, Karzoun NA, Benter IF, et al. Functional significance of activation of calcium/calmodulin-dependent protein kinase II in angiotensin II-induced vascular hyperplasia and hypertension. Hypertension. 2002;39(2 Pt 2):704-709.
Rao GN, Lassègue B, Alexander RW, Griendling KK. Angiotensin II stimulates phosphorylation of high-molecular-mass cytosolic phospholipase A2 in vascular smooth-muscle cells. Biochem J. 1994;299(Pt 1):197-201.
Rönkkö S. Purification and characterization of phospholipase A2 from bovine prostate. Int J Androl. 1992;15(5):394-406.
Weisser H, Ziemssen T, Krieg M. In vitro modulation of steroid 5α-reductase activity by phospholipases in epithelium and stroma of human benign prostatic hyperplasia. Steroids. 2001;66(6):521-528.
Gratzke C, Weinhold P, Reich O, et al. Transient receptor potential A1 and cannabinoid receptor activity in human normal and hyperplastic prostate: relation to nerves and interstitial cells. Eur Urol. 2010;57(5):902-910.
Tokanovic S, White CW, Malone DT, Exintaris B, Ventura S. Characterisation of the prostanoid receptor mediating inhibition of smooth muscle contractility in the rat prostate gland. Naunyn-Schmiedeberg's Arch Pharmacol. 2010;381(4):321-328.